AY

Adam Young

Senior Manager, Mechanical Engineering at Third Pole Therapeutics

Adam Young has extensive work experience in various engineering roles. Adam started their career at Stoneridge Electronics as a Principal Manufacturing Engineer in the Occupant Safety Group, where they worked for a decade. Adam then joined Insulet Corporation as a Manufacturing Engineer in the Automation Group. After that, they worked at Aspect Medical Systems, first as a Senior Manufacturing Engineer and later as a Product Development Engineer. Adam then moved to Covidien, where they held the position of Senior Design Engineer upon the acquisition of Aspect. At Corindus Vascular Robotics, Adam worked as a Senior Advanced Manufacturing Engineer and later as the Manager of Electro-Mechanical Engineering in R&D. Adam then worked at DOTS Technology Corporation as the Lead Mechanical Engineer. Recently, they held positions at Cognex Corporation, where they started as the Manager of Logistics Design Engineering and then became the Senior Manager of Hardware Engineering in the Logistics department. Adam's most recent role is as the Senior Manager of Mechanical Engineering at Third Pole Therapeutics.

Adam Young attended Northeastern University from 1992 to 1997, where they earned a Bachelor of Science in Mechanical Engineering Technology (BSMET). Adam also received a certification in Six Sigma Black Belt from Air Academy/Pollak, although the specific details of when they obtained this certification are not provided.

Location

Boston, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Third Pole Therapeutics

Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team’s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies. Our first product is being designed to be a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. We believe our novel approach of creating NO on demand has the promise to create new markets by enabling the worldwide use of inhaled NO in settings outside of acute care.